Logo image of ABOS

ACUMEN PHARMACEUTICALS INC (ABOS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ABOS - US00509G2093 - Common Stock

2.15 USD
+0.03 (+1.42%)
Last: 12/19/2025, 8:26:51 PM
2.11 USD
-0.04 (-1.86%)
After Hours: 12/19/2025, 8:26:51 PM
Fundamental Rating

1

ABOS gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. ABOS may be in some trouble as it scores bad on both profitability and health. ABOS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ABOS had negative earnings in the past year.
In the past year ABOS has reported a negative cash flow from operations.
ABOS had negative earnings in each of the past 5 years.
ABOS had a negative operating cash flow in each of the past 5 years.
ABOS Yearly Net Income VS EBIT VS OCF VS FCFABOS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -93.76%, ABOS is not doing good in the industry: 74.48% of the companies in the same industry are doing better.
ABOS's Return On Equity of -143.12% is on the low side compared to the rest of the industry. ABOS is outperformed by 64.27% of its industry peers.
Industry RankSector Rank
ROA -93.76%
ROE -143.12%
ROIC N/A
ROA(3y)-27.08%
ROA(5y)-28.29%
ROE(3y)-32.76%
ROE(5y)-32.44%
ROIC(3y)N/A
ROIC(5y)N/A
ABOS Yearly ROA, ROE, ROICABOS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ABOS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABOS Yearly Profit, Operating, Gross MarginsABOS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for ABOS has been increased compared to 1 year ago.
The number of shares outstanding for ABOS has been increased compared to 5 years ago.
Compared to 1 year ago, ABOS has a worse debt to assets ratio.
ABOS Yearly Shares OutstandingABOS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
ABOS Yearly Total Debt VS Total AssetsABOS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -4.85, we must say that ABOS is in the distress zone and has some risk of bankruptcy.
ABOS's Altman-Z score of -4.85 is on the low side compared to the rest of the industry. ABOS is outperformed by 62.19% of its industry peers.
A Debt/Equity ratio of 0.29 indicates that ABOS is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.29, ABOS is not doing good in the industry: 69.57% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF N/A
Altman-Z -4.85
ROIC/WACCN/A
WACCN/A
ABOS Yearly LT Debt VS Equity VS FCFABOS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 6.02 indicates that ABOS has no problem at all paying its short term obligations.
ABOS's Current ratio of 6.02 is fine compared to the rest of the industry. ABOS outperforms 62.38% of its industry peers.
A Quick Ratio of 6.02 indicates that ABOS has no problem at all paying its short term obligations.
ABOS's Quick ratio of 6.02 is fine compared to the rest of the industry. ABOS outperforms 63.89% of its industry peers.
Industry RankSector Rank
Current Ratio 6.02
Quick Ratio 6.02
ABOS Yearly Current Assets VS Current LiabilitesABOS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

0

3. Growth

3.1 Past

ABOS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -62.04%.
EPS 1Y (TTM)-62.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -3.90% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-22.21%
EPS Next 2Y4.84%
EPS Next 3Y10.21%
EPS Next 5Y-3.9%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ABOS Yearly Revenue VS EstimatesABOS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2030 2031 2032 50M 100M 150M 200M
ABOS Yearly EPS VS EstimatesABOS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ABOS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABOS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABOS Price Earnings VS Forward Price EarningsABOS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABOS Per share dataABOS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.84%
EPS Next 3Y10.21%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ABOS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ACUMEN PHARMACEUTICALS INC

NASDAQ:ABOS (12/19/2025, 8:26:51 PM)

After market: 2.11 -0.04 (-1.86%)

2.15

+0.03 (+1.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-25 2026-03-25/amc
Inst Owners63.38%
Inst Owner Change-4.94%
Ins Owners1.61%
Ins Owner Change0%
Market Cap130.23M
Revenue(TTM)N/A
Net Income(TTM)-133.35M
Analysts89.09
Price Target6.63 (208.37%)
Short Float %1.02%
Short Ratio2.11
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.31%
Min EPS beat(2)-23.92%
Max EPS beat(2)28.53%
EPS beat(4)2
Avg EPS beat(4)1.76%
Min EPS beat(4)-26.63%
Max EPS beat(4)29.06%
EPS beat(8)3
Avg EPS beat(8)-5.77%
EPS beat(12)6
Avg EPS beat(12)-1.34%
EPS beat(16)6
Avg EPS beat(16)-15.63%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-23.53%
PT rev (3m)-14.47%
EPS NQ rev (1m)14.48%
EPS NQ rev (3m)11.06%
EPS NY rev (1m)10.79%
EPS NY rev (3m)10.79%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.4
P/tB 1.4
EV/EBITDA N/A
EPS(TTM)-2.22
EYN/A
EPS(NY)-1.54
Fwd EYN/A
FCF(TTM)-2.04
FCFYN/A
OCF(TTM)-2.04
OCFYN/A
SpS0
BVpS1.54
TBVpS1.54
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -93.76%
ROE -143.12%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.08%
ROA(5y)-28.29%
ROE(3y)-32.76%
ROE(5y)-32.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -352%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.02
Quick Ratio 6.02
Altman-Z -4.85
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)197.72%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-62.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12%
EPS Next Y-22.21%
EPS Next 2Y4.84%
EPS Next 3Y10.21%
EPS Next 5Y-3.9%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-49.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26.58%
EBIT Next 3Y653.25%
EBIT Next 5YN/A
FCF growth 1Y-169.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-169.11%
OCF growth 3YN/A
OCF growth 5YN/A

ACUMEN PHARMACEUTICALS INC / ABOS FAQ

What is the fundamental rating for ABOS stock?

ChartMill assigns a fundamental rating of 1 / 10 to ABOS.


What is the valuation status for ABOS stock?

ChartMill assigns a valuation rating of 0 / 10 to ACUMEN PHARMACEUTICALS INC (ABOS). This can be considered as Overvalued.


What is the profitability of ABOS stock?

ACUMEN PHARMACEUTICALS INC (ABOS) has a profitability rating of 0 / 10.